Other
Side Effects
0
Pipeline Programs↗
5
Active Trials↗
5
Companies Involved↗
Side Effects is an early-stage landscape with 0 programs across 5 companies. The most active players are UCB, GSK, Chiesi Farmaceutici S.p.A..
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
No pipeline programs currently tracked for this disease.
Analysis
Trial Status
49
clinical trials
Completed28 · 57%
Unknown status10 · 20%
Terminated5 · 10%
Active, not recruiting2 · 4%
Recruiting2 · 4%
Withdrawn1 · 2%
Other1 · 2%
Clinical Trials
Trial Activity
49 trials
Changing to Nonprotease Inhibitor Treatment to Improve Side Effects
Completed·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT00021463·342 enrolled
Effects of Uridine Supplementation on Metabolic Side Effects of Stavudine and Zidovudine
Completed·NNational Center for Complementary and Integrative Health (NCCIH)·Phase 2·NCT00471614·3 enrolled
Low Dose Ketamine Infusion for Analgesia in the Emergency Department to Reduce Side Effects
Completed·—·Phase 4·NCT05518877·48 enrolled
Muscle-Related Side Effects of Statins: Functional Impact, Mechanisms, and Potential Relief With Vitamin D Supplementation
Completed·—·N/A·NCT01493648·78 enrolled
Study of Nasal Symptom Relief and Side Effects in Hayfever Patients Treated With Aerius (Desloratadine)(P03442)
Completed·—·Phase 4·NCT00805584·311 enrolled
Page 1 of 4
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)